Metronidazole Noridem

Metronidazole, the active ingredient in Metronidazole Noridem, is a nitroimidazole presented as an injectable solution for intravenous use. It treats anaerobic bacterial infections and certain protozoal diseases in adult and pediatric patients when prescribed by a qualified clinician. The drug is supplied in a sterile vial that can be diluted in compatible IV fluids before administration.

GNH USA supplies Metronidazole Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Metronidazole is a nitroimidazole antibiotic that targets anaerobic bacteria and susceptible protozoa. It is employed in several recognised clinical situations. - Anaerobic bacterial infections: eradicates susceptible anaerobes, reducing tissue damage and systemic spread. - Bacterial vaginosis: restores normal vaginal flora by eliminating over‑growth of anaerobic organisms. - Trichomoniasis: kills Trichomonas vaginalis, relieving symptoms and preventing recurrence. - Amebic liver abscess: eliminates Entamoeba histolytica trophozoites, facilitating resolution of hepatic lesions. - Clostridioides difficile infection: suppresses toxin‑producing C. difficile, aiding clinical recovery.

Metronidazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal upset. - Metallic taste: temporary alteration of taste perception. - Diarrhea: loose stools that usually resolve after therapy. - Headache: mild to moderate cranial pain. - Dizziness: occasional light‑headedness. - Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects: - Seizures: neurologic events requiring immediate medical attention. - Peripheral neuropathy: tingling or numbness of extremities. - Severe allergic reactions: anaphylaxis, angioedema, or rash. - Stevens‑Johnson syndrome: life‑threatening skin eruption. - Hepatotoxicity: elevated liver enzymes or liver injury. - Neutropenia: marked reduction in white blood cells.

Before initiating therapy, clinicians should consider several safety measures. - Assess renal function: adjust therapy in patients with severe impairment. - Monitor liver enzymes: watch for signs of hepatotoxicity during prolonged use. - Avoid alcohol: risk of a disulfiram‑like reaction with flushing and tachycardia. - Use caution in pregnancy: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Metronidazole can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: can increase anticoagulant effect and bleeding risk. - Lithium: may raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma levels. - Phenytoin: may reduce metronidazole effectiveness. - Theophylline: may elevate theophylline concentrations, requiring dose adjustment.